Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system

Abstract Proton pump inhibitors (PPIs) were widely used. Observational studies suggested increasing risk of kidney injury in patients with PPIs treatment. We gathered six PPI regimens and adverse reports of acute kidney injury (AKI) and chronic kidney disease (CKD) based on US FDA Adverse Event Repo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bin Wu, Dan Li, Ting Xu, Min Luo, Zhiyao He, Yuwen Li
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/883788a03d4641199f0700b59cdcd163
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:883788a03d4641199f0700b59cdcd163
record_format	dspace
spelling	oai:doaj.org-article:883788a03d4641199f0700b59cdcd1632021-12-02T13:30:22ZProton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system10.1038/s41598-021-83099-y2045-2322https://doaj.org/article/883788a03d4641199f0700b59cdcd1632021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-83099-yhttps://doaj.org/toc/2045-2322Abstract Proton pump inhibitors (PPIs) were widely used. Observational studies suggested increasing risk of kidney injury in patients with PPIs treatment. We gathered six PPI regimens and adverse reports of acute kidney injury (AKI) and chronic kidney disease (CKD) based on US FDA Adverse Event Reporting System (FAERS) database from 2004 to 2019. We employed reporting odds ratio (ROR) to detect signals. Finally, we identified 3187 PPIs-associated AKI cases and 3457 PPIs-associated CKD cases. We detected significant signals between PPIs and AKI as well as CKD. The signal strength was stronger for CKD (ROR = 8.80, 95% CI 8.49–9.13) than AKI (ROR = 3.95, 95% CI 3.81–4.10), while dexlansoprazole performed stronger association for CKD (ROR = 34.94, 95% CI 30.89–39.53) and AKI (ROR = 8.18, 95% CI 7.04–9.51) than the other five PPIs. The median time from PPIs use to event occurrence was 23 days for AKI and 177 days for CKD. PPIs-associated AKI resulted larger proportion of death, life-threatening, hospitalization and disability events than PPIs-associated CKD. By mining the FAERS big data, we provided more information between PPIs use and the AKI and CKD events. PPIs rational use should be repeatedly stressed.Bin WuDan LiTing XuMin LuoZhiyao HeYuwen LiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Bin Wu Dan Li Ting Xu Min Luo Zhiyao He Yuwen Li Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system
description	Abstract Proton pump inhibitors (PPIs) were widely used. Observational studies suggested increasing risk of kidney injury in patients with PPIs treatment. We gathered six PPI regimens and adverse reports of acute kidney injury (AKI) and chronic kidney disease (CKD) based on US FDA Adverse Event Reporting System (FAERS) database from 2004 to 2019. We employed reporting odds ratio (ROR) to detect signals. Finally, we identified 3187 PPIs-associated AKI cases and 3457 PPIs-associated CKD cases. We detected significant signals between PPIs and AKI as well as CKD. The signal strength was stronger for CKD (ROR = 8.80, 95% CI 8.49–9.13) than AKI (ROR = 3.95, 95% CI 3.81–4.10), while dexlansoprazole performed stronger association for CKD (ROR = 34.94, 95% CI 30.89–39.53) and AKI (ROR = 8.18, 95% CI 7.04–9.51) than the other five PPIs. The median time from PPIs use to event occurrence was 23 days for AKI and 177 days for CKD. PPIs-associated AKI resulted larger proportion of death, life-threatening, hospitalization and disability events than PPIs-associated CKD. By mining the FAERS big data, we provided more information between PPIs use and the AKI and CKD events. PPIs rational use should be repeatedly stressed.
format	article
author	Bin Wu Dan Li Ting Xu Min Luo Zhiyao He Yuwen Li
author_facet	Bin Wu Dan Li Ting Xu Min Luo Zhiyao He Yuwen Li
author_sort	Bin Wu
title	Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system
title_short	Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system
title_full	Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system
title_fullStr	Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system
title_full_unstemmed	Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system
title_sort	proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of us fda adverse event reporting system
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/883788a03d4641199f0700b59cdcd163
work_keys_str_mv	AT binwu protonpumpinhibitorsassociatedacutekidneyinjuryandchronickidneydiseasedataminingofusfdaadverseeventreportingsystem AT danli protonpumpinhibitorsassociatedacutekidneyinjuryandchronickidneydiseasedataminingofusfdaadverseeventreportingsystem AT tingxu protonpumpinhibitorsassociatedacutekidneyinjuryandchronickidneydiseasedataminingofusfdaadverseeventreportingsystem AT minluo protonpumpinhibitorsassociatedacutekidneyinjuryandchronickidneydiseasedataminingofusfdaadverseeventreportingsystem AT zhiyaohe protonpumpinhibitorsassociatedacutekidneyinjuryandchronickidneydiseasedataminingofusfdaadverseeventreportingsystem AT yuwenli protonpumpinhibitorsassociatedacutekidneyinjuryandchronickidneydiseasedataminingofusfdaadverseeventreportingsystem
_version_	1718392926654955520

Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system

Ejemplares similares